Inspire Pharmaceuticals (ISPH) Licenses Novel Glaucoma Technology; Addition Of New Ophthalmic Program Enhances Pipeline
10/19/2005 5:12:03 PM
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced an agreement to license exclusively several patents from the Wisconsin Alumni Research Foundation (WARF) for use in developing and commercializing new therapeutics for treating glaucoma, a disease that affects an estimated 2.2 million people in the United States. These patents are based upon research conducted by Dr. Paul L. Kaufman, Professor and Chairman of Ophthalmology and Visual Sciences at the University of Wisconsin, and Dr. Benjamin Geiger, Professor of Molecular Cell and Tumor Biology, and Dean Of Biology at the Weizmann Institute of Science in Israel.
comments powered by